Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYB1904 in Chronic Spontaneous Urticaria
NCT06509334Phase 2Recruiting
- Sponsor
- Jemincare
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ozureprubart in chronic spontaneous urticaria (CSU) (3 arms), sponsored by Jemincare. Primary endpoint: Urticaria Activity Score over 7 days at 16 weeks. Started Aug 2024; status: recruiting.
02
Drugs
ozureprubart
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06509334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509334.